Gallant Therapeutics

📍 SAN DIEGO, United States🗓 Founded 2018👥 43 employees💰 Last funded Dec 2020
Biotechnology Research🌐 gallanttherapeutics.com
Website LinkedIn
Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallant’s team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Gallant Therapeutics?
Gallant Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Gallant Therapeutics last raise funding?
The most recent investment in Gallant Therapeutics recorded on gritt.io was in December 2020.
When was Gallant Therapeutics founded?
Gallant Therapeutics was founded in 2018.
What industry is Gallant Therapeutics in?
Gallant Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Gallant Therapeutics based?
Gallant Therapeutics is headquartered in SAN DIEGO, United States.